Table 6.
CLL11 trial baseline characteristics
| Obinutuzumab/chlorambucil | Rituximab/chlorambucil | Chlorambucil | |
|---|---|---|---|
| N | 333 | 330 | 118 |
| Age (years, median) | 74 (39–89) | 73 (40–90) | 72 (43–87) |
| CIRS score (median) | 8 (0–22) | 8 (0–18) | 8 (0–18) |
| Creatinine clearance (mL/min), median | 62.5 | 62.6 | 63.8 |
| Binet Stage A (%) | 22 | 22 | 20 |
| Binet Stage B (%) | 43 | 41 | 42 |
| Binet Stage C (%) | 35 | 37 | 37 |
| Unmutated IgHV (%) | 62 | 61 | 59 |
| Deletion 17p (%) | 7 | 7 | 10 |
Note: Data from Goede et al.45
Abbreviations: CIRS, Cumulative Illness Rating Scale; IgHV, immunoglobulin variable region heavy chain; CLL, chronic lymphocytic leukemia.